-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
-
Spanish PM says unregulated AI could be 'devastating'
-
हॉप्त् कलेक्शन: पैसा हमारे बारे में एक इंसान के रूप में क्या प्रकट करता है
-
Yu, 13, smashes record again with second Asian Games gold
-
Συλλογή Haupt: Τι αποκαλύπτει το χρήμα για εμάς τους ανθρώπους
-
Switzerland to play without Xhaka over fake Covid certificate
-
TradersYard Shifts Focus to Futures Trading
-
From Korean Chipmakers to Leveraged Semiconductor ETFs: STARTRADER Launches 49 New 24/7 Stock and ETF CFDs
-
ハウプト・コレクション:お金が人間について明かすこと
-
Thai badminton player first doping case at Asian Games: testers
-
하우프트 컬렉션: 돈이 우리 인간에 대해 드러내는 것
-
Колекція Гаупта: Що гроші розповідають про нас, людей
-
Indonesia doing 'everything' but struggling to curb fires
-
German far-right AfD poll winner says Merz 'twilight' has begun
-
Sbírka Haupt: Co o nás lidech prozrazují peníze
-
Flights scrapped, evacuations urged as Typhoon Dujuan nears Japan
-
North and South Korea fight out draw in niggly Asian Games clash
-
China confirms Xi to visit US this week for Trump talks
-
Officials say man shot, wounded by ICE agent in Texas
-
مجموعة هاوبت: ما يكشفه المال عنا نحن البشر
-
豪普特收藏:金錢如何揭露人類的本質
-
Colecția Haupt: Ce ne dezvăluie banii despre noi, oamenii
-
Kolekcja Haupta: Co pieniądze mówią o nas, ludziach
-
Sisters of jailed Pakistan ex-PM Imran Khan arrested
-
The Haupt Collection: What Money Reveals About Us as Human Beings
-
African players in Europe: Semenyo brace helps City top table
-
Barcelona enter new era aiming to retain Women's Champions League crown
-
'For my family': India boxer beats hardship, injury to go for Games gold
-
US has deported 25,000 to third countries under secretive deals: report
-
Indonesia doing 'everything' but still struggling to curb fires
-
Three South Korean soldiers injured in DMZ blast: military
-
Once decried as 'human cockfighting', MMA wants Olympic spot
-
New Zealanders pick endangered black robin as Bird of the Year
-
China's Yu, 13, great for swimming says multiple Olympic medallist
-
Asia stocks rise on AI, US-China trade talks optimism
-
Putin's party set to retain power after Russia vote hit by cyberattacks, drones
-
Malaysia's 'elephant whisperer' fights to save Borneo's endangered giants
-
Germany's Merz under pressure after bruising state election losses
-
'I live in fear': 1.5 million Pakistani children sexually exploited online
-
Messi, Miami frustrated in 2-2 draw with San Diego
-
Cowboys beat Commanders, Vikings down Bears as star QBs injured
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
O.Krause--BTB